

Article

A Straightforward Synthesis of Functionalized *cis*-Perhydroisoquinolin-1-ones

Federica Arioli ¹, Maria Pérez ² , Celeste Are ¹, Elies Molins ³ , Joan Bosch ¹ and Mercedes Amat ^{1,*} 

¹ Laboratory of Organic Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain; fede.arioli@hotmail.it (F.A.); cele.are@ub.edu (C.A.); joanbosch@ub.edu (J.B.)

² Department of Nutrition, Food Sciences and Gastronomy, Faculty of Pharmacy and Food Sciences, and Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, 08921 Santa Coloma de Gramanet, Spain; mariaperez@ub.edu

³ Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Cerdanyola, Spain; elies.molins@icmab.es

* Correspondence: amat@ub.edu; Tel.: +34-93-402-4540

Academic Editors: David Díez and María Ángeles Castro

Received: 15 January 2019; Accepted: 30 January 2019; Published: 3 February 2019



Abstract: Base-catalyzed annulation reactions of 5,6-dihydro-2(1*H*)-pyridones with Nazarov-type reagents are reported. The effect of the solvent polarity and the concentration of the reagents is studied. The process involves two successive Michael additions and stereoselectively provides functionalized *cis*-perhydroisoquinolin-1-ones.

Keywords: 5,6-dihydro-2(1*H*)-pyridone; Nazarov reagents; perhydroisoquinoline; Michael addition; stereoselectivity

1. Introduction

Nitrogen heterocycles exhibit a broad range of significant biological and pharmacological activities, and many of them have been developed as therapeutic drugs [1,2].

In particular, the partially or totally reduced isoquinoline ring system is present in a large number of biologically active natural products (such as the alkaloids of the yohimbine [3,4], manzamine [5], and madangamine [6] groups) and medicinally useful synthetic compounds (e.g., the HIV protease inhibitors saquinavir and nelfinavir [7,8], the antimigraine drugs tezampanel and LY466195 [9], and the antiobesity agent AMG 076 [10]) (Figure 1).

Together with the intramolecular Diels–Alder cyclization of suitable azatrienes [11,12], one of the most straightforward approaches for the construction of the hydroisoquinoline ring system involves the generation of the carbocyclic ring by an annulation reaction from appropriate 5,6-dihydro-2(1*H*)-pyridone derivatives. The latter strategy was developed some years ago in our laboratory using the classical Diels–Alder methodology with a variety of dienes [13]. Bearing in mind that Nazarov reagents (γ,δ -unsaturated β -keto esters) are able to participate in double Michael addition reactions with α,β -unsaturated carbonyl derivatives, we envisaged an alternative annulation procedure to directly access functionalized hydroisoquinolines from 5,6-dihydro-2(1*H*)-pyridones.





Figure 1. Hydroisoquinoline-containing bioactive natural products and synthetic compounds.

Nazarov reagents are versatile annulating agents, extensively used in a variety of Robinson-type and double Michael addition annulations [14–16]. In the former, the reagent sequentially acts as an electrophilic Michael acceptor and as a nucleophile to promote an aldol condensation. In the latter, however, it successively acts as a nucleophilic Michael donor and an electrophilic Michael acceptor, a reactivity pattern that has been successfully applied to assemble pentacyclic yohimbine-type derivatives from unsaturated indolo[2,3-*a*]quinolizidine-derived lactams [17–19].

2. Results and Discussion

Compounds **6a,b,c** and **8**, which incorporate an additional phenylsulfonyl or ethoxycarbonyl activating electron-withdrawing group conjugated to the carbon-carbon double bond, were selected as the starting dihydropyridones.


Lactams **6a,b**, bearing an easily removable phenylsulfonyl group, were prepared in acceptable overall yield from 2-piperidone (**1a**) by bis-sulfonylation, followed by reaction with either (Boc)₂O or MeI, and subsequent stepwise *m*-CPBA oxidation of the resulting *N*-substituted piperidones **3a,b** via unsaturated sulfenyl and sulfinyl derivatives **4a,b** and **5a,b**. A similar reaction sequence from *N*-tosyl-2-piperidone **3c** led to unsaturated lactam **6c** in low overall yield. Due to their instability, lactams **6a,b,c** were used in the annulation step without purification. In turn, ethoxycarbonyl lactam **8** was prepared in high yield from *N*-Boc-2-piperidone (**1b**) via seleno derivative **7**, as outlined in Scheme 1.



Scheme 1. Preparation of the starting unsaturated lactams.

To study the annulation reactions, we initially used unsaturated lactam **6a** and the Nazarov reagent **9** [14], which incorporates a methyl group at the terminal olefinic carbon, in the presence of Cs_2CO_3 , the most commonly used base for the generation of Nazarov enolates [20]. Reagent **9** has been used extensively by Deslongchamps to generate *cis*-decalin derivatives [20,21]. The reaction was carried out at room temperature, using an excess (6 equiv.) of Cs_2CO_3 in CH_2Cl_2 at different concentrations (from 50 mM to 5 mM). In all cases, the double Michael addition reaction occurred satisfactorily, although with only moderate stereoselectivity, to give 3:1 C-8 stereoisomeric mixtures of *cis*-hydroisoquinolones **10a** (*cis* Me/ SO_2Ph) and **10b** (*trans* Me/ SO_2Ph), the chemical yield increasing (79% yield at 5 mM) with the dilution (Table 1, entries 1–3). Trace amounts of the monoaddition product **11** were detected by NMR, indicating that the annulation involves two successive Michael addition reactions. In contrast, when acetonitrile was used as the solvent the yield was very low (entry 4). Remarkably, the use of KF as the base in a polar solvent such as methanol (entry 5) resulted in a reversal of the stereoselectivity, leading to a mixture of bicyclic lactams **10a** and **10b**, in which the *trans* Me/ SO_2Ph isomer predominated (56% yield, ratio 1:2). The influence of the solvent polarity on the stereoselectivity of annulation reactions of **9** with β -keto esters has previously been observed [21]. The facial selectivity when using Cs_2CO_3 as the base can be attributed to the coordination of the Cs^+ cation to the oxygen atoms of both the Nazarov reagent and the starting lactam [19].

Table 1. Reaction of unsaturated lactam **6a** with Nazarov reagent **9**.



Entry	Base	Solvent	Concentration (mM)	Yield (%)	a/b Ratio
1	Cs_2CO_3	CH_2Cl_2	50	47	3:1
2	Cs_2CO_3	CH_2Cl_2	25	56	3:1
3	Cs_2CO_3	CH_2Cl_2	5	79	3:1
4	Cs_2CO_3	MeCN	5	10	–
5	KF	MeOH	5	56	1:2

The relative Me/ SO_2Ph *cis* configuration of bicyclic lactam **10a** was unambiguously established by X-ray crystallographic analysis (Figure 2).





Figure 2. ORTEP plot of the X-ray structure of bicyclic lactam **10a**.

Unsaturated lactam **6b** behaved similarly to lactam **6a** in the annulation reaction with Nazarov reagent **9**, although the yields were slightly lower, probably due to the lower electrophilicity of the

Michael acceptor as a consequence of the absence of an electron-withdrawing group on the piperidone nitrogen. *cis*-Hydroisoquinolone **12a**, with a *cis* Me/SO₂Ph relationship, was stereo-selectively formed (4:1 **12a**/**12b** ratio) when the reaction was performed in CH₂Cl₂ solution using Cs₂CO₃ as the base (Table 2, entries 1 and 2), the yield once again being higher with increasing dilution (40% yield at 5 mM). As before, a reversal of the stereoselectivity was observed and the *trans* Me/SO₂Ph isomer predominated when using polar solvents, either MeOH in the presence of KF (1:4 ratio; entry 3) or DMF in the presence of Cs₂CO₃ (1:5 ratio; entry 4). The Me/SO₂Ph *cis* relationship of the adducts **10a** and **12a** was maintained unchanged after an additional treatment (20 h, rt) with Cs₂CO₃ in CH₂Cl₂ or KF in MeOH, thus suggesting the non-reversibility of the cyclization step.

Table 2. Reaction of unsaturated lactam **6b** with Nazarov reagent **9**.



Entry	Base	Equiv Base	Equiv (9)	Solvent	Concentration (mM)	Yield (%)	a/b Ratio
1	Cs ₂ CO ₃	6	3	CH ₂ Cl ₂	100	28	4:1
2	Cs ₂ CO ₃	6	3	CH ₂ Cl ₂	5	40	4:1
3	KF	6	3	MeOH	5	51	1:4
4	Cs ₂ CO ₃	4	2	DMF	5	45	1:5

The relative configuration of both hydroisoquinolones, **12a** and **12b**, was unambiguously established by X-ray crystallographic analysis (Figure 3).





Figure 3. ORTEP plots of the X-ray structures of bicyclic lactams **12a** and **12b**.

The activating phenylsulfonyl group of bicyclic lactams **10a**, **12a**, and **12b** was stereoselectively removed, with retention of configuration, by treatment with sodium amalgam [22] to give the respective *cis*-hydroisoquinolones **13a**, **14a**, and **14b** (Scheme 2). Alternatively, removal of the *N*-Boc protecting group of hydroisoquinolones **10a** and **13a** quantitatively afforded the potentially useful *N*-unsubstituted derivatives **15** and **16**, respectively. The *cis* ring function was evident from the observation of a positive NOE effect between the 4a and 8a methine protons.


To expand the scope of the methodology and access hydroisoquinolones lacking the methyl substituent on the B ring, we decided to study double Michael annulations using the silylated Nazarov reagent **17** [17], which constitutes a stable synthetic equivalent of the original Nazarov reagent (methyl or ethyl 3-oxo-4-pentenoate) [15] that avoids the polymerization problems associated with the latter under basic conditions.



Scheme 2. Desulfonylation reactions and removal of the *N*-Boc protecting group.


As expected, the Cs_2CO_3 -promoted annulation of the Nazarov reagent **17** with unsaturated lactam **6a** under the usual reaction conditions (5 mM in CH_2Cl_2 as the solvent) stereoselectively afforded *cis*-hydroisoquinolone **18a**, in which protodesilylation had occurred, in acceptable yield (Table 3, entry 1). The yield was not improved by increasing the excess of reagent and base (entry 2) and was lower when operating at a higher concentration (entry 3) or when using KF in MeOH as the solvent (entry 4). Similar moderate yields were obtained in the generation of *cis*-hydroisoquinolones **18b** and **18c** from lactams **6b** (entries 5–7) and **6c** (entry 8) under a variety of conditions.

Table 3. Reactions of unsaturated lactams **6a–c** with Nazarov reagent **17**.



Entry	Unsaturated Lactam	Base	Equiv Base	Equiv (15)	Solvent	Concentration (mM)	Product	Yield (%)
1	6a	Cs_2CO_3	6	3	CH_2Cl_2	5	18a	47
2	6a	Cs_2CO_3	10	5	CH_2Cl_2	5	18a	47
3	6a	Cs_2CO_3	6	3	CH_2Cl_2	20	18a	20
4	6a	KF	6	3	MeOH	5	18a	20
5	6b	Cs_2CO_3	6	3	CH_2Cl_2	5	18b	35
6	6b	Cs_2CO_3	6	3	CH_2Cl_2	100	18b	21
7	6b	KF	6	3	MeOH	5	18b	20
8	6c	Cs_2CO_3	6	3	CH_2Cl_2	5	18c	32

Remarkably, the yield of the annulation with the silylated Nazarov reagent **17** was higher when using unsaturated lactam **8**, which incorporates an ester group as an additional activating substituent. Operating under the previously optimized reaction conditions, *cis*-hydroisoquinolone **19** was obtained in 60% yield (Scheme 3).



Scheme 3. Reaction of unsaturated lactam **8** with the silylated Nazarov reagent **17**.

In conclusion, base-promoted annulation reactions of Nazarov reagents **9** and **17** with 5,6-dihydro-2(1*H*)-pyridones bearing an additional activating electron-withdrawing group α to the lactam carbonyl constitute a straightforward procedure for the stereoselective synthesis of highly substituted *cis*-hydroisoquinolin-2-ones. In the reactions with the methyl-substituted reagent **9**, leading

to 8-substituted derivatives, the use of Cs_2CO_3 in CH_2Cl_2 leads to *cis*-hydroisoquinolones with a *cis* 8-Me/8a-SO₂Ph relationship as the major stereoisomers. The stereoselectivity is reversed in a polar solvent such as DMF or when the annulation is performed using KF in MeOH.

The methodology developed here provides access to polyfunctionalized bicyclic scaffolds with potential use as precursors of bioactive hydroisoquinoline-containing natural products and synthetic derivatives.

3. Materials and Methods

3.1. General Information

All air sensitive manipulations were carried out under a dry argon or nitrogen atmosphere. THF and CH_2Cl_2 were dried using a column solvent purification system. Analytical thin-layer chromatography was performed on SiO_2 (silica gel 60A 35–70 μm , Carlo Erba, Val de Reuil Cedex, France), and the spots were located with 1% aqueous KMnO_4 . Chromatography refers to flash chromatography and was carried out on SiO_2 (SDS silica gel 60 ACC, 35–75 mm, 230–240 mesh ASTM). NMR spectra were recorded at 300 or 400 MHz (^1H) and 100.6 MHz (^{13}C), and chemical shifts are reported in δ values downfield from TMS or relative to residual chloroform (7.26 ppm, 77.0 ppm) as an internal standard. Data are reported in the following manner: chemical shift, multiplicity, coupling constant (J) in hertz (Hz), integrated intensity, and assignment (when possible). Assignments and stereochemical determinations are given only when they are derived from definitive two-dimensional NMR experiments (HSQC-COSY). IR spectra were performed in an Avatar 320 FT-IR spectrophotometer (Thermo Nicolet, Madison, WI, USA) and only noteworthy IR absorptions (cm^{-1}) are listed. High resolution mass spectra (HMRS; LC/MSD TOF, Agilent Technologies, Santa Clara, CA, USA) were performed by Centres Científics i Tecnològics de la Universitat de Barcelona.

3.2. Preparation of the Starting Unsaturated Lactams

3,3-Bis(phenylthio)-2-piperidone (2). *n*-BuLi (25.5 mL of a 1.6 M solution in hexane, 40.8 mmol) was added under an argon atmosphere at -78°C to a solution of δ -valerolactam (**1a**, 4 g, 40.82 mmol) in anhydrous THF (100 mL). The solution was stirred for 30 minutes, and then TMSCl (5.2 mL, 40.8 mmol) was added. The solution was stirred at room temperature for 30 minutes, and then re-cooled to -78°C . LDA (45 mL, 2 M solution in THF/heptane/ethylbenzene, 89.8 mmol) was added, and the solution was stirred for 30 minutes. Then, PhSSPh (19.5 g, 89.8 mmol) in anhydrous THF (50 mL) was added, and the resulting solution was stirred at room temperature for 1 h. After this time, NH_4Cl was added, and the organic layer was extracted with EtOAc. The combined organic extracts were dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) of the residue gave lactam **2** (6.61 g, 51% yield): IR (ATR Pike) ν (cm^{-1}): 3260 (NH), 1661 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ = 1.72–1.90 (m, 2H, H-5), 1.97 (t, J = 6.2 Hz, 2H, H-4), 3.18 (dt, J = 2.4, 6.0 Hz, 2H, H-6), 6.26 (br. s, 1H, NH), 7.32–7.34 (m, 6H, H_{AR}), 7.63–7.65 (m, 4H, H_{AR}); HRMS (ESI) calcd for [$\text{C}_{17}\text{H}_{18}\text{NOS}_2 + \text{H}^+$]: 316.0824, found: 316.062714b (detailed data in supplementary materials).

3,3-Bis(phenylthio)-1-(tert-butoxycarbonyl)-2-piperidone (3a). *n*-BuLi (6.1 mL of a 1.4 M solution in hexane, 8.54 mmol) was added under an argon atmosphere at -78°C to a solution of lactam **2** (2.25 g, 7.12 mmol) in anhydrous THF (100 mL), and the resulting solution was stirred for 1 h. Then, Boc_2O (2.30 g, 10.68 mmol) was added, and the mixture was stirred at -78°C for 1 h. After this time, saturated NH_4Cl was added, and the mixture was extracted with EtOAc. The combined organic extracts were dried over Na_2SO_4 and filtered, and the solvent was removed under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) of the residue gave *N*-Boc derivative **3a** (2.92 g, 99% yield): IR (ATR Pike) ν (cm^{-1}): 1717 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ = 1.53 [s, 9H, $(\text{CH}_3)_3\text{C}$], 1.94 (m, 2H, H-5), 2.05 (m, 2H, H-4), 3.60 (t, J = 6.1 Hz, 2H, H-6), 7.33–7.42 (m, 6H, H_{AR}), 7.68 (m, 4H, H_{AR}); $^{13}\text{C-NMR}$ (400 MHz, CDCl_3): δ = 20.1 (C-5), 28.0 [$(\text{CH}_3)_3\text{C}$], 35.1 (C-4), 46.7 (C-6), 68.6 (C-3), 83.2

[(CH₃)₃C], 128.7 (4CH_{AR}), 129.6 (2CH_{AR}), 130.9 (2C_{AR}), 136.8 (4CH_{AR}), 153.8 (CO), 168.3 (CO); HRMS (ESI) calcd for [C₂₂H₂₅NO₃S₂ + Na⁺]: 438.1168, found: 438.117.

3,3-Bis(phenylthio)-1-methyl-2-piperidone (3b). *n*-BuLi (8.54 mL of a 1.6 M solution in hexane, 13.67 mmol) was added under an argon atmosphere at −78 °C to a solution of lactam **2** (3.60 g, 11.39 mmol) in anhydrous THF (200 mL), and the resulting mixture was stirred at −78 °C for 1 h. Then, MeI (1.06 mL, 17.09 mmol) was added, and the solution was stirred at room temperature for 1 h. The reaction was quenched by addition of saturated NH₄Cl, and the mixture was extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) of the residue afforded *N*-methyl derivative **3b** (3.7 g, 98% yield): IR (ATR Pike) ν (cm^{−1}): 1642 (NCO); ¹H-NMR (400 MHz, CDCl₃): δ = 1.86–1.91 (m, 2H, H-5), 1.97–1.99 (m, 2H, H-4), 2.92 (s, 3H, CH₃), 3.16 (t, *J* = 6.4 Hz, 2H, H-6), 7.31–7.38 (m, 6H, H_{AR}), 7.63–7.65 (m, 4H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 19.6 (C-5), 34.0 (C-4), 35.8 (CH₃), 50.1 (C-6), 66.0 (C-3), 128.6 (4CH_{AR}), 129.3 (2CH_{AR}), 131.6 (2C_{AR}), 136.6 (4CH_{AR}); HRMS (ESI) calcd for [C₁₈H₁₉NOS₂ + H⁺]: 330.0981, found: 330.0977.

3,3-Bis(phenylthio)-1-(*p*-toluenesulfonyl)-2-piperidone (3c). *n*-BuLi (1.2 mL of a 1.6 M solution in hexane, 1.9 mmol) was added at −78 °C to a solution of lactam **2** (500 mg, 1.58 mmol) in anhydrous THF (25 mL), and the resulting mixture was stirred at −78 °C for 1 h. Then, TsCl (452 mg, 2.37 mmol) was added, and the solution was stirred at room temperature overnight. The reaction was quenched by addition of saturated NH₄Cl, and the mixture was extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) afforded *N*-tosyl derivative **3c** (264 mg, 52% yield): IR (ATR Pike) ν (cm^{−1}): 1683 (NCO), 1169 (SO₂); ¹H-NMR (400 MHz, CDCl₃): δ = 1.55 (s, 2H, H-5), 2.02 (s, 2H, H-4), 2.49 (s, 3H, CH₃), 3.46 (br. s, 2H, H-6), 7.19–7.40 (m, 12H, H_{AR}), 7.93 (d, *J* = 8.4 Hz, 2H, H_{AR}).

1-(*tert*-Butoxycarbonyl)-3-(phenylthio)-5,6-dihydro-2(1H)-pyridone (4a). *m*-Chloroperbenzoic acid (1.09 g, technical grade 70%, 766 mg pure oxidant, 6.33 mmol) in CH₂Cl₂ (100 mL) was added to a solution of lactam **3a** (2.64 g, 6.33 mmol) in CH₂Cl₂ (200 mL) at −78 °C. The solution was stirred at this temperature for 2 h and then for 30 minutes at room temperature. After this time, a saturated solution of NaHCO₃ was added, the mixture was extracted with CH₂Cl₂, and the organic solvent was removed under reduced pressure. The crude product was purified by flash chromatography (95:5 hexane-EtOAc) to afford unsaturated lactam **4a** (1.88 g, 97% yield): IR (ATR Pike) ν (cm^{−1}): 1762 (CO), 1715 (CO); ¹H-NMR (300 MHz, CDCl₃): δ = 1.54 [s, 9H, (CH₃)₃C], 2.39 (td, *J* = 6.6, 4.8 Hz, 2H, H-5), 3.84 (t, *J* = 6.6 Hz, 2H, H-6), 6.08 (t, *J* = 4.8 Hz, 1H, H-4), 7.33–7.41 (m, 2H, H_{AR}), 7.47–7.50 (m, 2H, H_{AR}), 7.66–7.70 (m, 1H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 25.3 (C-5), 28.0 [(CH₃)₃C], 43.7 (C-6), 83.4 [(CH₃)₃C], 128.8 (CH_{AR}), 129.5 (2CH_{AR}), 131.0 (C-3, C_{AR}), 134.8 (2CH_{AR}), 135.5 (C-4), 152.8 (CO), 161.7 (CO); HRMS (ESI) calcd for [C₁₆H₁₉NO₃S + Na⁺]: 328.0978, found: 328.0975.

1-Methyl-3-(phenylthio)-5,6-dihydro-2(1H)-pyridone (4b). Operating as described for the preparation of compound **4a**, from a solution of lactam **3b** (280 mg, 0.85 mmol) in CH₂Cl₂ (20 mL) and *m*-CPBA (210 mg, technical grade 70%, 0.85 mmol) in CH₂Cl₂ (20 mL), unsaturated lactam **4b** was obtained (160 mg, 86% yield) as a yellow foam: ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.34 (td, *J* = 7.2, 4.8 Hz, 2H, H-5), 3.04 (s, 1H, CH₃), 3.40 (t, *J* = 7.2 Hz, 2H, H-6), 5.81 (t, *J* = 4.8 Hz, 1H, H-4), 7.35–7.39 (m, 3H, H_{AR}), 7.48–7.50 (m, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 24.6 (C-5), 34.9 (CH₃), 47.6 (C-6), 128.5 (CH_{AR}), 129.4 (2CH_{AR}), 130.8 (C-4), 132.0, 134.4 (C-3, C_{AR}), 134.6 (2CH_{AR}), 162.9 (CO).

3-(Phenylthio)-1-(*p*-toluenesulfonyl)-5,6-dihydro-2(1H)-pyridone (4c). Operating as described for the preparation of compound **4a**, from a solution of lactam **3c** (264 mg, 0.58 mmol) in CH₂Cl₂ (15 mL) and *m*-CPBA (142 mg, technical grade 70%, 0.58 mmol) in CH₂Cl₂ (15 mL), unsaturated lactam **4c** was obtained (123 mg, 61% yield) as a yellow foam: IR (ATR Pike) ν (cm^{−1}): 1683 (CO), 1166 (SO₂); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.43 (s, 3H, CH₃), 2.48 (td, *J* = 6.3, 4.8 Hz, 2H, H-5), 4.04 (t, *J* = 6.3 Hz, 2H, H-6), 6.08 (t, *J* = 4.8 Hz, 1H, H-4), 7.30–7.37 (m, 7H, H_{AR}), 7.93 (d, *J* = 8.4 Hz,

2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 21.6 (CH₃), 25.9 (C-5), 44.1 (C-6), 128.7 (CH_{AR}), 128.9 (CH_{AR}), 129.4 (CH_{AR}), 129.6 (CH_{AR}), 130.7 (C_{AR}), 134.5 (CH_{AR}), 135.6 (C-3, C_{AR}), 136.2 (C-4), 144.9 (CH_{AR}), 161.1 (NCO); HRMS (ESI) calcd for [C₁₈H₁₇NO₃S₂ + H⁺]: 360.0723, found: 360.0720.

1-(tert-Butoxycarbonyl)-3-(phenylsulfinyl)-5,6-dihydro-2(1H)-pyridone (5a). *m*-Chloroperbenzoic acid (1.51 g, technical grade 70%, 1.06 g pure oxidant, 6.14 mmol) in CH₂Cl₂ (100 mL) was added to a solution of phenylthio derivative **4a** (1.884 g, 6.14 mmol) in CH₂Cl₂ (200 mL) at −78 °C. The solution was stirred at this temperature for 1.5 h. Then, a saturated solution of NaHCO₃ was added, the mixture was extracted with CH₂Cl₂, and the organic solvent was removed under reduced pressure. The crude product was purified by flash chromatography (95:5 hexane-EtOAc) to afford sulfinyl derivative **5a** (1.39 g, 70% yield): IR (ATR Pike) ν (cm^{−1}): 1762 (CO), 1719 (CO), 1099, 1049 (SO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.51 [s, 9H, (CH₃)₃C], 2.55–2.75 (m, 2H, H-5), 3.59 (ddd, *J* = 13.2, 10.4, 5.2 Hz, 1H, H-6), 4.05 (dtd, *J* = 13.2, 5.2, 1.1 Hz, H-6), 7.45–7.47 (m, 3H, H_{AR}), 7.57 (td, *J* = 3.6, 1.2 Hz, 1H, H-4), 7.79–7.81 (m, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 24.9 (C-5), 27.9 [(CH₃)₃C], 43.2 (C-6), 83.8 [(CH₃)₃C], 125.6 (2CH_{AR}), 129.1 (2CH_{AR}), 131.3 (CH_{AR}), 142.3 (C-4), 142.6, 143.7 (C_{AR}, C-3), 151.9 (CO), 160.2 (CO); HRMS (ESI) calcd for [C₁₆H₁₉NO₄S + Na⁺]: 344.0927, found: 344.0927.

1-(Methyl)-3-(phenylsulfinyl)-5,6-dihydro-2(1H)-pyridone (5b). Operating as described for the preparation of compound **5a**, from a solution of phenylthio derivative **4b** (163 mg, 0.74 mmol) in CH₂Cl₂ (15 mL) and *m*-CPBA (183 mg, technical grade 70%, 0.74 mmol) in CH₂Cl₂ (20 mL), sulfinyl derivative **5b** was obtained (100 mg, 57% yield): IR (ATR Pike) ν (cm^{−1}): 1652 (CO), 1043 (SO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.53–2.74 (2m, 2H, H-5), 2.90 (s, 3H, CH₃), 3.38–3.46 (dd, *J* = 8.8, 6.8 Hz, 2H, H-6), 7.31 (t, *J* = 4.8 Hz, 1H, H-4), 7.44–7.45 (m, 3H, H_{AR}), 7.78–7.81 (m, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 24.0 (C-5), 33.7 (CH₃), 46.8 (C-6), 125.5 (2CH_{AR}), 128.8 (2CH_{AR}), 131.0 (CH_{AR}), 138.1 (C-4), 140.6, 143.8 (C_{AR}, C-3), 160.1 (NCO); HRMS (ESI) calcd for [C₁₂H₁₃NO₂S + H⁺]: 236.074, found: 236.0741.

*3-(Phenylsulfinyl)-1-(*p*-toluenesulfonyl)-5,6-dihydro-2(1H)-pyridone (5c)*. Operating as described for the preparation of compound **5a**, from a solution of phenylthio derivative **4c** (55 mg, 0.12 mmol) in CH₂Cl₂ (3 mL) and *m*-CPBA (30 mg, technical grade 70%, 0.12 mmol) in CH₂Cl₂ (3 mL), sulfinyl derivative **5c** was obtained. This compound was used in the next step without further purification: IR (ATR Pike) ν (cm^{−1}): 1683, (NCO), 1362 (SO₂), 1170 (SO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.43 (s, 3H, CH₃), 2.67–2.81 (m, 2H, H-5), 3.78–3.86 (m, 1H, H-6), 4.11–4.20 (m, 1H, H-6), 7.27 (d, *J* = 7.6 Hz, 2H, H_{AR}), 7.36–7.41 (m, 3H, H_{AR}), 7.52 (dd, *J* = 4.4, 3.6 Hz, 1H, H-4), 7.63–7.66 (m, 2H, H_{AR}), 7.82 (d, *J* = 8.0 Hz, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 21.6 (CH₃), 25.3 (C-5), 43.8 (C-6), 125.1 (2CH_{AR}), 128.3 (2CH_{AR}), 129.1 (2CH_{AR}), 129.4 (2CH_{AR}), 131.3 (CH_{AR}), 135.1 (C_{AR}), 142.8 (C-4), 143.2, 145.1 (C_{AR}, C-3), 159.7 (NCO).

1-(tert-Butoxycarbonyl)-3-(phenylsulfonyl)-5,6-dihydro-2(1H)-pyridone (6a). *m*-Chloroperbenzoic acid (1.06 mg, technical grade 70%, 745 mg pure oxidant, 4.32 mmol) in CH₂Cl₂ (150 mL) was added to a solution of sulfinyl derivative **5a** (1.39 g, 4.32 mmol) in CH₂Cl₂ (60 mL) at −78 °C. The solution was stirred at room temperature for 6 h. Then, a saturated solution of NaHCO₃ was added, the mixture was extracted with CH₂Cl₂, and the organic solvent was removed under reduced pressure to afford sulfonyl derivative **6a**, which was used in the next step without purification: IR (ATR Pike) ν (cm^{−1}): 1721 (CO), 1689 (CO), 1446 (SO₂), 1143 (SO₂); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.49 [s, 9H, (CH₃)₃C], 2.67 (td, *J* = 6.0, 4.0 Hz, 2H, H-5), 3.87 (t, *J* = 6.8 Hz, 2H, H-6), 7.51–7.53 (m, 2H, H_{AR}), 7.60 (t, *J* = 7.6 Hz, 1H, H_{AR}), 8.05 (dm, *J* = 7.2 Hz, 2H, H_{AR}), 8.08 (t, *J* = 4.4 Hz, 1H, H-4); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 25.0 (C-5), 27.9 [(CH₃)₃C], 42.9 (C-6), 84.2 [(CH₃)₃C], 128.7 (2CH_{AR}), 129.3 (2CH_{AR}), 133.5 (CH_{AR}), 138.7, 139.5 (C-3, C_{AR}), 151.4 (CO), 152.2 (C-4), 157.8 (CO); HRMS (ESI) calcd for [C₁₆H₁₉NO₅S + H⁺]: 338.1057, found: 338.1066.

1-Methyl-3-(phenylsulfonyl)-5,6-dihydro-2(1H)-pyridone (6b). Operating as described for the preparation of compound **6a** (reaction time 20 h), from a solution of sulfinyl derivative **5b** (100 mg, 0.42 mmol) in CH₂Cl₂ (10 mL) and *m*-CPBA (104 mg, technical grade 70%, 0.42 mmol) in CH₂Cl₂ (10 mL), sulfonyl derivative **6b** was obtained. This compound was used in the next step without purification: IR (ATR Pike) ν (cm⁻¹): 1662 (NCO), 1306 (SO₂), 1151 (SO₂); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.67 (td, *J* = 7.2, 4.4 Hz, 2H, H-5), 2.93 (s, 3H, CH₃), 3.46 (t, *J* = 7.2 Hz, 2H, H-6), 7.51 (tm, *J* = 7.6 Hz, 2H, H_{AR}), 7.57 (m, 1H, H_{AR}), 7.87 (t, *J* = 4.4 Hz, 1H, H-4), 8.05 (dm, *J* = 7.6 Hz, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 24.3 (C-5), 34.4 (CH₃), 46.6 (C-6), 128.6 (2CH_{AR}), 129.1 (2CH_{AR}), 133.4 (CH_{AR}), 140.0 (C-3, C_{AR}), 148.4 (C-4), 159.0 (CO); HRMS (ESI) calcd for [C₁₂H₁₃NO₃S + H⁺]: 252.0689, found: 252.0679.

3-(Phenylsulfonyl)-1-(p-toluenesulfonyl)-5,6-dihydro-2(1H)-pyridone (6c). Operating as described for the preparation of compound **6a** (reaction time 20 h), from a solution of sulfinyl derivative **5c** (45 mg, 0.12 mmol) in CH₂Cl₂ (6 mL) and *m*-CPBA (30 mg, technical grade 70%; 21 mg pure oxidant, 0.12 mmol) in CH₂Cl₂ (6 mL), sulfonyl derivative **6c** was obtained. This compound was used in the next step without purification: IR (ATR Pike) ν (cm⁻¹): 1695 (NCO), 1362 (SO₂), 1157 (SO₂); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 2.42 (s, 1H, CH₃), 2.79 (td, *J* = 6.4, 4.4 Hz, 2H, H-5), 4.04 (t, *J* = 6.0 Hz, 2H, H-6), 7.29 (d, *J* = 8.0 Hz, 2H, H_{AR}), 7.47–7.51 (m, 2H, H_{AR}), 7.57 (tt, *J* = 7.6, 1.2 Hz, 1H, H_{AR}), 7.85 (d, *J* = 8.0 Hz, 2H, H_{AR}), 7.96 (d, *J* = 8.0 Hz, 2H, H_{AR}), 8.06 (t, *J* = 4.4 Hz, 1H, H-4); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 21.6 (CH₃), 25.7 (C-5), 43.5 (C-6), 128.4 (2CH_{AR}), 128.8 (2CH_{AR}), 129.1 (2CH_{AR}), 129.6 (2CH_{AR}), 133.7 (CH_{AR}), 134.9 (C_{AR}), 137.8 (CH_{AR}), 139.0 (C-3), 145.3 (C_{AR}), 153.2 (C-4), 157.2 (NCO).

1-(tert-Butoxycarbonyl)-3-(ethoxycarbonyl)-3-(phenylselenenyl)-2-piperidone (7). Lithium bis(trimethyl silyl)amide (11.1 mL of a 1 M solution in THF, 11.1 mmol) was slowly added at –78 °C under an argon atmosphere to a solution of lactam **1b** (1.0 g, 5.05 mmol) in anhydrous THF (100 mL), and the solution was stirred for 1 h. Then, ethyl chloroformate (532 μ L, 5.56 mmol) and, after 1 h of continuous stirring at –78 °C, a solution of PhSeCl (1.48 g, 7.58 mmol) in anhydrous THF (10 mL) were added to the solution. The mixture was stirred for a further 1 h and poured into saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc, and the combined organic extracts were dried, filtered, and concentrated under reduced pressure. Flash chromatography (8:2 hexane-EtOAc) of the resulting oil gave the seleno derivative **7** (1.79 g, 83% yield) as a yellow foam: IR (ATR Pike) ν (cm⁻¹): 1718 (CO); ¹H-NMR (300 MHz, CDCl₃): δ = 1.27 (t, *J* = 7.2 Hz, 3H, CH₂CH₃), 1.54 [s, 9H, (CH₃)₃C], 1.73 (m, 1H, H-5), 1.84 (m, 1H, H-5), 2.01 (ddd, *J* = 13.8, 10.2, 5.7 Hz, 1H, H-4), 2.28 (dt, *J* = 13.8, 6.0 Hz, 1H, H-4), 3.52 (m, 1H, H-6), 3.61 (ddd, *J* = 13.2, 8.4, 5.4 Hz, 1H, H-6), 4.22 (qd, *J* = 7.2, 3.3 Hz, 2H, CH₂CH₃), 7.31 (t, *J* = 7.2 Hz, 2H, H_{AR}), 7.41 (t, *J* = 7.2 Hz, 1H, H_{AR}), 7.65 (t, *J* = 7.2 Hz, 2H, H_{AR}); HRMS (ESI) calcd for [C₁₉H₂₅NO₅Se + Na⁺]: 450.0787, found: 450.0788.

1-(tert-Butoxycarbonyl)-3-(ethoxycarbonyl)-5,6-dihydro-2(1H)-pyridone (8). H₂O₂ (900 μ L, 29.35 mmol) and pyridine (405 μ L, 5.03 mmol) were added at room temperature to a solution of seleno lactam **7** (1.79 g, 4.19 mmol) in CH₂Cl₂ (300 mL), and the resulting solution was stirred at room temperature for 30 minutes. Water was then added, and the mixture was extracted with CH₂Cl₂. The combined organic extracts were dried, filtered, and concentrated under reduced pressure. Flash chromatography (8:2 hexane-EtOAc) of the resulting oil gave unsaturated lactam **8** (981 mg, 87% yield) as a yellow foam: IR (ATR Pike) ν (cm⁻¹): 1715 (CO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.33 (t, *J* = 6.8 Hz, 3H, CH₂CH₃), 1.54 [s, 9H, (CH₃)₃C], 2.52 (td, *J* = 6.4, 4.4 Hz, 2H, H-5), 3.88 (t, *J* = 6.4 Hz, 2H, H-6), 4.29 (q, *J* = 6.8 Hz, 2H, CH₂CH₃), 7.48 (t, *J* = 4 Hz, 1H, H-4); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 14.1 (CH₂CH₃), 24.7 (C-5), 28.0 [(CH₃)₃C], 43.0 (C-6), 61.5 (CH₂CH₃), 83.6 [(CH₃)₃C], 130.9 (C-3), 148.5 (C-4), 160.0 (CO), 164.0 (CO); HRMS (ESI) calcd for [C₁₃H₁₉NO₅ + Na⁺]: 292.1155, found: 292.1166.

3.3. General Procedure for the Double Michael Addition Reactions

A solution of unsaturated lactam **6a,b,c** or **8** (1 equiv.) in anhydrous CH₂Cl₂, MeCN or MeOH was added at 0 °C under an argon atmosphere to a solution of the Nazarov reagent (**9** or **15**) and Cs₂CO₃

or KF in anhydrous CH₂Cl₂, MeCN or MeOH, and the resulting mixture was allowed to warm slowly to room temperature. After 20 h of stirring at room temperature, the mixture was concentrated under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) of the residue afforded the corresponding adduct/s (**10a,b**, **12a,b**, **16a,b,c** or **17**) as yellow foams (detailed data in supplementary materials).

cis-2-(*tert*-Butoxycarbonyl)-6-hydroxy-5-(methoxycarbonyl)-8-methyl-1-oxo-8a-(phenylsulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinolines **10a** and **10b**. Operating as described above in the general procedure, from unsaturated lactam **6a** (800 mg, 2.28 mmol) in anhydrous CH₂Cl₂ (200 mL), Nazarov reagent **9** (1.07 g, 7.5 mmol), and Cs₂CO₃ (4.9 g, 15 mmol) in anhydrous CH₂Cl₂ (250 mL), *cis*-hydroisoquinolones **10a** (*cis* Me/SO₂Ph isomer) and **10b** (*trans* Me/SO₂Ph isomer) were obtained (ratio 3:1, 890 mg, 79% yield). Compound **10a**: IR (ATR Pike) ν (cm⁻¹): 1727 (CO), 1654 (CO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.08 (d, *J* = 6.4 Hz, 3H, CH₃), 1.50 [s, 9H, (CH₃)₃C], 1.89 (m, 1H, H-7), 2.32 (dm, *J* = 14.8 Hz, 1H, H-4), 2.40 (m, 2H, H-8, H-7), 2.70 (dddd, *J* = 14.8, 13.6, 5.2, 3.6 Hz, 1H, H-4), 3.23 (td, *J* = 12.8, 4.0 Hz, 1H, H-3), 3.74 (dm, *J* = 12.8 Hz, 1H, H-3), 3.82 (s, 3H, CH₃O) 3.92 (br. s, 1H, H-4a), 7.49 (td, *J* = 7.6, 2.0 Hz, 2H, H_{AR}), 7.63 (td, *J* = 7.6, 1.2 Hz, 1H, H_{AR}), 7.96–7.99 (dd, *J* = 7.6, 1.2 Hz, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 14.0 (CH₃), 23.3 (C-4), 27.8 [(CH₃)₃C], 29.3 (C-4a), 30.8 (C-8), 35.0 (C-7), 42.9 (C-3), 51.8 (CH₃O), 77.4 (C-8a), 83.6 [(CH₃)₃C], 96.6 (C-5), 128.3 (2CH_{AR}), 130.9 (2CH_{AR}), 134.1 (CH_{AR}), 137.0 (C_{AR}), 151.8 (CO), 167.1 (CO), 171.5, 171.6 (CO, C-6); HRMS (ESI) calcd for [C₂₃H₂₉NO₈S + Na⁺]: 502.1506, found: 502.1511. Compound **10b**: ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.06 (d, *J* = 6.8 Hz, 3H, CH₃), 1.53 [s, 9H, (CH₃)₃C], 1.69 (ddd, *J* = 13.2, 3.6, 1H, H-4), 2.17 (d, *J* = 18.4 Hz, 1H, H-7), 2.44 (dd, *J* = 14.0, 2.8 Hz, 1H, H-4), 2.79 (m, 1H, H-8), 3.15 (dd, *J* = 18.0, 6.0 Hz, 1H, H-7), 3.39 (td, *J* = 12.8, 3.2 Hz, 1H, H-3), 3.71 (dd, *J* = 12.8, 1.2, 1H, H-4a), 3.86 (s, 3H, CH₃O) 3.94 (dt, *J* = 12.4, 2.4 Hz, H-3), 7.54 (t, *J* = 7.2 Hz, 2H, H_{AR}), 7.68 (td, *J* = 8.0, 1.2 Hz, 1H, H_{AR}), 7.89 (d, *J* = 8.0 Hz, 2H, H_{AR}); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 20.4 (CH₃), 27.7 (C-4), 27.9 [(CH₃)₃C], 30.1 (C-8), 33.2 (C-7), 33.2 (C-4a), 45.7 (C-3), 51.8 (CH₃O), 77.9 (C-8a), 83.5 [(CH₃)₃C], 96.8 (C-5), 128.5 (2CH_{AR}), 131.0 (2CH_{AR}), 134.3 (CH_{AR}), 134.9 (C_{AR}), 151.5 (CO), 166.3 (CO), 171.0, 171.8 (CO, C-6).

cis-6-Hydroxy-5-(methoxycarbonyl)-2,8-dimethyl-1-oxo-8a-(phenylsulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinolines **12a** and **12b**. Operating as described in the general procedure, from unsaturated lactam **6b** (220 mg, 0.87 mmol) in anhydrous MeOH (160 mL), Nazarov reagent **9** (372 mg, 2.62 mmol), and KF (304 mg, 5.24 mmol) in anhydrous MeOH (10 mL), *cis*-hydroisoquinolones **12a** (*cis* Me/SO₂Ph isomer) and **12b** (*trans* Me/SO₂Ph isomer) were obtained (ratio 1:5, 175 mg, 51% yield). Compound **12a**: IR (ATR Pike) ν (cm⁻¹): 1646 (CO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.09 (d, *J* = 6.8 Hz, 3H, CH₃), 1.90 (dd, *J* = 18.5, 2.0 Hz, 1H, H-7), 2.30 (dq, *J* = 17.6, 2.4 Hz, 1H, H-4), 2.39 (dm, *J* = 18.5 Hz, 1H, H-7), 2.48 (m, 1H, H-8), 2.67–2.73 (m, 1H, H-4), 2.96 (s, 3H, CH₃N), 3.21 (m, 2H, H-3), 3.84 (s, 3H, CH₃O), 7.53 (t, *J* = 7.6 Hz, 2H, H_{AR}), 7.65 (t, *J* = 7.2 Hz, 1H, H_{AR}), 8.07 (dd, *J* = 7.6 Hz, 1H, H_{AR}), 12.34 (s, 1H, OH); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 13.8 (CH₃), 23.0 (C-4), 29.6 (C-4a), 30.5 (C-8), 35.3 (C-7), 35.8 (NCH₃), 46.3 (C-3), 51.8 (CH₃O), 75.5 (C-8a), 96.6 (C-5), 128.3 (2CH_{AR}), 131.0 (2CH_{AR}), 133.9 (CH_{AR}), 138.0, (C_{AR}), 165.0 (CO), 171.9 (C-6, CO); HRMS (ESI) calcd for [C₁₉H₂₃NO₆S + H⁺]: 394.1319, found: 394.1323. Compound **12b**: ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.02 (d, *J* = 7.2 Hz, 3H, CH₃), 1.69 (qd, *J* = 12.8, 4.4 Hz, 1H, H-4), 2.16 (dd, *J* = 18.0, 1.6 Hz, 1H, H-7), 2.32 (dm, *J* = 12.8 Hz, 1H, H-4), 2.77 (s, 3H, CH₃N), 3.04 (t, *J* = 6.8 Hz, 1H, H-8), 3.04–3.10 (m, 2H, H-7, H-3), 3.25 (td, *J* = 13.2, 4.0 Hz, 1H, H-3), 3.60 (dd, *J* = 12.8, 4.0 Hz, 1H, H-4a), 3.81 (s, 3H, CH₃O), 7.51 (t, *J* = 7.6 Hz, 2H, H_{AR}), 7.62 (t, *J* = 7.2 Hz, 1H, H_{AR}), 7.90 (t, *J* = 7.2 Hz, 1H, H_{AR}), 12.2 (s, 1H, OH); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 20.6 (CH₃), 28.1 (C-4), 29.7 (C-8), 33.2 (C-7), 33.9 (C-4a), 35.8 (CH₃N), 48.8 (C-3), 51.8 (CH₃O), 75.8 (C-8a), 97.4 (C-5), 128.3 (CH_{AR}), 130.8 (CH_{AR}), 133.9 (C-3), 136.7, (C_{AR}), 164.9 (CO), 171.1 (C-6), 171.9 (CO).

cis-2-(*tert*-Butoxycarbonyl)-6-hydroxy-5-(methoxycarbonyl)-1-oxo-8a-(phenylsulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (**18a**). Operating as described in the general procedure, from unsaturated lactam **6a** (150 mg, 0.44 mmol) in anhydrous CH₂Cl₂ (65 mL), Nazarov reagent **17** (268 mg, 1.33 mmol), and Cs₂CO₃ (865 mg, 2.66 mmol) in anhydrous CH₂Cl₂ (20 mL), *cis*-hydroisoquinolone **18a** was

obtained (96 mg, 47% yield): IR (ATR Pike) ν (cm^{-1}): 1733 (C=O), 1653 (NCO); $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): δ = 1.55 [s, 9H, $(\text{CH}_3)_3\text{C}$], 1.64 (m, 1H, H-4), 2.12–2.21 (m, 3H, 2H-7, H-8), 2.46–2.54 (m, 2H, H-8, H-4), 3.62–3.74 (m, 2H, 2H-3), 3.85 (s, 3H, CH_3O), 3.96 (dd, J = 9.6, 3.6 Hz, H-4a), 7.53 (t, J = 7.6 Hz, 2H, H_{AR}), 7.68 (t, J = 7.6, 1.2 Hz, 1H, H_{AR}), 7.86 (d, J = 7.6, 1.2 Hz, 2H, H_{AR}), 12.34 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): δ = 25.8 (C-8), 26.4 (C-7), 27.9 [$(\text{CH}_3)_3\text{C}$], 28.3 (C-4), 32.6 (C-4a), 44.3 (C-3), 51.9 (CH_3O), 74.1 (C-8a), 83.6 [$(\text{CH}_3)_3\text{C}$], 98.4 (C-5), 128.5 (2CH_{AR}), 130.8 (2CH_{AR}), 134.3 (CH_{AR}), 135.0 (C_{AR}), 151.8 (CO), 166.7 (CO), 171.5, 173.9 (CO, C-6); HRMS (ESI) calcd for $[\text{C}_{22}\text{H}_{27}\text{NO}_8\text{S} + \text{NH}_4^+]$: 483.1796, found: 483.1789.

cis-6-Hydroxy-5-(methoxycarbonyl)-2-methyl-1-oxo-8a-(phenylsulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (**18b**). Operating as described in the general procedure, from unsaturated lactam **6b** (60 mg, 0.24 mmol) in anhydrous CH_2Cl_2 (35 mL), Nazarov reagent **17** (144 mg, 0.71 mmol), and Cs_2CO_3 (469 mg, 1.44 mmol) in anhydrous CH_2Cl_2 (15 mL), *cis*-hydroisoquinolone **18b** was obtained (32 mg, 35% yield): IR (ATR Pike) ν (cm^{-1}): 1653 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): δ = 1.97 (m, 1H, H-4), 2.00–2.15 (m, 3H, H-7, 2H-8), 2.35 (m, 1H, H-7), 2.46–2.54 (ddt, J = 13.8, 8.8, 4.2 Hz, 1H, H-4), 2.93 (s, 3H, CH_3N), 3.17 (ddt, J = 12.8, 9.4, 3.8 Hz, 1H, H-3), 3.27 (m, 1H, H-3), 3.84 (s, 3H, CH_3O), 4.01 (dd, J = 6.4, 3.6 Hz, H-4a), 7.51 (t, J = 7.6 Hz, 2H, H_{AR}), 7.64 (t, J = 7.6 Hz, 1H, H_{AR}), 7.88 (d, J = 7.6 Hz, 2H, H_{AR}), 12.40 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): δ = 26.1 (C-7), 26.2 (C-4), 27.2 (C-8), 32.1 (C-4a), 35.8 (CH_3N), 46.9 (C-3), 51.8 (CH_3O), 71.6 (C-8a), 97.7 (C-5), 128.6 (2CH_{AR}), 130.1 (2CH_{AR}), 133.8 (CH_{AR}), 136.7 (C_{AR}), 164.5 (CO), 171.8, 172.9 (CO, C-6); HRMS calcd for $[\text{C}_{18}\text{H}_{21}\text{NO}_6\text{S} + \text{H}^+]$: 380.1162, found: 380.1158.

cis-6-Hydroxy-5-(methoxycarbonyl)-1-oxo-8a-(phenylsulfonyl)-2-(*p*-toluenesulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (**18c**). Operating as described in the general procedure, from unsaturated lactam **6c** (50 mg, 0.12 mmol) in anhydrous CH_2Cl_2 (20 mL), Nazarov reagent **17** (73 mg, 0.36 mmol) and Cs_2CO_3 (234 mg, 0.72 mmol) in anhydrous CH_2Cl_2 (5 mL), *cis*-hydroisoquinolone **18c** was obtained (20 mg, 32% overall yield for the three steps). IR (ATR Pike) ν (cm^{-1}): 1653 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): δ = 1.85–1.93 (m, 2H, H-4, H-7), 1.99–2.04 (m, 2H, H-7, H-8), 2.29–2.35 (m, 1H, H-8), 2.50 (s, 3H, CH_3), 2.75–2.70 (m, 1H, H-4), 3.84 (s, 3H, CH_3O) 3.91 (m, 1H, H-3), 4.01 (m, 1H, H-3), 7.22–7.34 (m, 6H, H_{AR}), 7.60 (td, J = 7.2, 1.2 Hz, 1H, H_{AR}), 7.91 (d, J = 8.8 Hz, 2H, H_{AR}), 12.34 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): δ = 21.7 (CH_3), 25.7 (C-8), 27.0 (C-7), 28.3 (C-4), 31.9 (C-4a), 43.8 (C-3), 52.0 (CH_3O), 73.1 (C-8a), 97.8 (C-5), 128.3–130.7 (CH_{AR}), 134.3 (CH_{AR}), 134.6, 135.2 (C_{AR} , CH_{AR}), 145.1 (C_{AR}), 165.5 (CO), 171.4, 172.9 (CO, C-6); HRMS (ESI) calcd for $[\text{C}_{24}\text{H}_{25}\text{NO}_8\text{S}_2 + \text{H}^+]$: 520.1094, found: 520.1108.

cis-2-(*tert*-Butoxycarbonyl)-8a-(ethoxycarbonyl)-6-hydroxy-5-(methoxycarbonyl)-1-oxo-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (**19**). Operating as described in the general procedure, from unsaturated lactam **8** (90 mg, 0.33 mmol) in anhydrous CH_2Cl_2 (60 mL), Nazarov reagent **17** (202 mg, 1 mmol), and Cs_2CO_3 (652 mg, 2 mmol) in anhydrous CH_2Cl_2 (5 mL), *cis*-hydroisoquinolone **19** was obtained (87 mg, 60% yield): IR (ATR Pike) ν (cm^{-1}): 1725 (CO), 1654 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): δ = 1.09 (d, J = 7.2 Hz, 3H, CH_2CH_3), 1.36 [s, 9H, $(\text{CH}_3)_3\text{C}$], 1.51 (ddd, J = 14.0, 12.0, 4.8 Hz, 1H, H-4), 1.90 (ddd, J = 14.0, 11.2, 7.2 Hz, 1H, H-8), 2.03 (dq, J = 14.0, 3.6 Hz, 1H, H-4), 2.18 (ddd, J = 18.4, 7.2, 2.0 Hz, 1H, H-7), 2.32 (dd, J = 14.0, 7.2 Hz, 1H, H-8), 2.63 (ddd, J = 18.4, 10.4, 8.0 Hz, 1H, H-7), 3.31 (dd, J = 11.6, 3.2 Hz, 1H, H-4a), 3.40 (td, J = 12.4, 3.6 Hz, 1H, H-3), 3.64 (s, 3H, CH_3O), 3.66 (ddd, J = 12.4, 4.8, 3.2 Hz, 1H, H-3), 4.05 (qd, J = 7.2, 2.4 Hz, 2H, CH_2CH_3), 12.18 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): δ = 13.9 (CH_2CH_3), 24.6 (C-8), 26.3 (C-7), 27.5 (C-4), 27.9 [$(\text{CH}_3)_3\text{C}$], 34.7 (C-4a), 45.7 (C-3), 51.7 (CH_3O), 56.1 (C-8a), 61.7 (CH_2CH_3), 83.4 [$(\text{CH}_3)_3\text{C}$], 98.0 (C-5), 152.7 (C-6), 170.4 (CO), 170.5 (CO), 171.9 (CO), 172.7 (CO); HRMS (ESI) calcd for $[\text{C}_{19}\text{H}_{27}\text{NO}_8 + \text{Na}^+]$: 420.1629, found: 420.1645.

3.4. General Procedure for the Desulfonylation Reactions

Na_2HPO_4 (50 equiv.) and sodium amalgam (25 equiv.) were added at -78°C under an argon atmosphere to a solution of the sulfonyl derivative **10a**, **12a** or **12b** (1 equiv.) in anhydrous methanol

(0.025 M), and the mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 2 h. The solution was then filtered and quenched with H_2O at low temperature. The mixture was concentrated under reduced pressure, and the resulting aqueous solution was extracted with EtOAc. The combined organic extracts were dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure. Flash chromatography (9:1 hexane-EtOAc) of the residue afforded the desulfurated compounds **13a**, **14a** or **14b** (detailed data in supplementary materials).

cis-2-(*tert*-Butoxycarbonyl)-6-hydroxy-5-(methoxycarbonyl)-8-methyl-1-oxo-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (*H*-8/*H*-8a *trans*, **13a**). Operating as described in the above general desulfonylation procedure, from a solution of sulfonyl derivative **10a** (580 mg, 1.21 mmol) in anhydrous methanol (50 mL), Na_2HPO_4 (8.60 g, 60.6 mmol), and sodium amalgam (6.77 g, 30.3 mmol), compound **13a** was obtained (357 mg, 87% yield): $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): $\delta = 1.05$ (d, $J = 6.0$ Hz, 3H, CH_3), 1.53 [s, 9H, $(\text{CH}_3)_3\text{C}$], 1.79 (dddd, $J = 19.2, 12.8, 11.2, 4.8$ Hz, 1H, H-4), 2.04 (m, 1H, H-7), 2.10 (m, 1H, H-4), 2.30 (m, 2H, H-8, H-8a), 2.46 (dd, $J = 19.2, 4.8$ Hz, 1H, H-7), 2.98 (dt, $J = 11.2, 4.0$ Hz, 1H, H-4a), 3.41 (td, $J = 12.8, 4.0$ Hz, 1H, H-3), 3.70–3.75 (m, 1H, H-3), 3.79 (s, 3H, CH_3O), 12.23 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): $\delta = 18.8$ (CH_3), 26.9 (C-8), 27.1 (C-4), 27.9 [$(\text{CH}_3)_3\text{C}$], 32.0 (C-4a), 36.8 (C-7), 45.2 (C-3), 50.5 (C-8a), 51.6 (CH_3O), 82.7 [$(\text{CH}_3)_3\text{C}$], 99.3 (C-5), 153.3 (CO), 169.0 (CO), 172.2, 173.1 (CO, C-6); HRMS (ESI) calcd for $[\text{C}_{17}\text{H}_{25}\text{NO}_6 + \text{Na}^+]$: 362.1574, found: 362.1579.

cis-6-Hydroxy-5-(methoxycarbonyl)-2-methyl-1-oxo-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (*H*-8/*H*-8a *trans*, **14a**). Operating as described in the general desulfonylation procedure, from a solution of sulfone **12a** (100 mg, 0.25 mmol) in anhydrous MeOH (10 mL), Na_2HPO_4 (1.81 g, 12.7 mmol), and sodium amalgam (1.42 g, 6.36 mmol), compound **14a** was obtained (48 mg, 76% yield) as a white foam: IR (ATR Pike) ν (cm^{-1}): 1645 (CO); $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): $\delta = 1.09$ (d, $J = 7.2$ Hz, 3H, CH_3), 1.90 (m, 1H, H-4), 1.94–2.10 (m, 2H, H-4, H-7), 2.24 (m, 2H, H-8, H-8a), 2.38 (d, $J = 18.4, 4.4$ Hz, 1H, H-7), 2.90 (m, 1H, H-4a), 2.92 (s, 3H, CH_3N), 3.21–3.25 (m, 2H, H-3), 3.79 (s, 3H, CH_3O), 12.30 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): $\delta = 19.2$ (CH_3), 26.5 (C-4), 27.4 (C-8a), 31.3 (C-4a), 34.8 (CH_3N), 37.1 (C-7), 47.2 (C-8), 48.8 (C-3), 51.5 (CH_3O), 99.1 (C-5), 170.7 (CO), 172.3 (C-6), 172.6 (CO); HRMS (ESI) calcd for $[\text{C}_{13}\text{H}_{20}\text{NO}_4 + \text{H}^+]$: 254.1387, found: 254.1387.

cis-6-Hydroxy-5-(methoxycarbonyl)-2-methyl-1-oxo-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (*H*-8/*H*-8a *cis*, **14b**). Operating as described in the general desulfonylation procedure, from a solution of sulfone **12b** (340 mg, 0.87 mmol) in anhydrous MeOH (10 mL), Na_2HPO_4 (6.134 g, 43.2 mmol), and sodium amalgam (4.836 g, 21.6 mmol), compound **14b** was obtained (137 mg, 62% yield) as a white foam: $^1\text{H-NMR}$ (400 MHz, CDCl_3 , COSY, g-HSQC): $\delta = 1.05$ (d, $J = 7.2$ Hz, 3H, CH_3), 1.86 (qd, $J = 12.0, 5.2$, 1H, H-4), 2.10 (dm, $J = 12.0$ Hz, 1H, H-4), 2.19 (dd, $J = 18.0, 2.0$ Hz, 1H, H-7), 2.657–2.64 (m, 12H, H-8, H-7), 2.67 (m, 1H, H-8a), 2.85–2.90 (m, 1H, H-4a), 3.00 (s, 3H, NCH_3), 3.24 (dq, $J = 12.0, 3.2$ Hz, 1H, H-3), 3.39 (td, $J = 12.0, 4.4$ Hz, 1H, H-3), 3.79 (s, 3H, CH_3O), 12.48 (s, 1H, OH); $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3): $\delta = 18.8$ (CH_3), 26.6 (C-4), 29.4 (C-8a), 31.9 (C-4a), 34.9 (CH_3N), 36.1 (C-7), 43.6 (C-8), 49.2 (C-3), 51.5 (CH_3O), 98.0 (C-5), 171.2 (CO), 172.6 (C-6, CO).

3.5. General Procedure for the Removal of the *N*-Boc Substituent

TFA (1:3 TFA/ CH_2Cl_2 ratio) was added to a solution of the *N*-Boc derivative **10a** or **13a** in anhydrous CH_2Cl_2 (0.05–0.06 M), and the mixture was stirred for 30 minutes at room temperature. Toluene (1 mL) was added to the resulting solution, and the mixture was concentrated under reduced pressure. After a second addition of toluene (1 mL) and concentration of the mixture, flash chromatography (7:3 to 3:7 hexane-EtOAc) of the residue afforded the deprotected compound **15** or **16**.

cis-6-Hydroxy-5-(methoxycarbonyl)-8-methyl-1-oxo-8a-(phenylsulfonyl)-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (*Me*/*SO}_2\text{Ph}* *cis*, **15**). Operating as described in the above general procedure, from a solution of the *N*-Boc derivative **10a** (23 mg, 0.048 mmol) in anhydrous CH_2Cl_2 (750 μL) and TFA (250 μL), compound **15** was obtained (18 mg, 98% yield): IR (ATR Pike) ν (cm^{-1}): 3352 (NH), 1668 (CO); $^1\text{H-NMR}$ (400

MHz, CDCl₃, COSY, g-HSQC): δ = 1.11 (d, J = 6.8 Hz, 3H, CH₃), 1.94 (dd, J = 17.6, 2.0 Hz, H-7), 2.32 (dm, J = 14.8 Hz, 1H, H-4), 2.45 (m, 1H, H-8), 2.50 (dm, J = 17.6 Hz, 1H, H-7), 2.65 (dddd, J = 14.8, 12.4, 5.6, 3.6 Hz, 1H, H-4), 3.16 (td, J = 12.4, 4.4 Hz, 1H, H-3), 3.27 (m, 1H, H-3), 3.85 (s, 3H, CH₃O), 3.97 (br.s, 1H, H-4a), 6.29 (br.s, 1H, NH), 7.53 (t, J = 7.2, Hz, 2H, H_{AR}), 7.65 (t, J = 7.2 Hz, 1H, H_{AR}), 8.06 (d, J = 7.2 Hz, 2H, H_{AR}), 12.33 (s, 1H, OH); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 13.7 (CH₃), 22.4 (C-4), 29.2 (C-4a), 30.1 (C-8), 35.2 (C-7), 38.7 (C-3), 51.8 (CH₃O), 75.1 (C-8a), 96.5 (C-5), 128.3 (2CH_{AR}), 130.6 (2CH_{AR}), 134.0 (CH_{AR}), 137.7 (C_{AR}), 167.0 (CO), 171.6, 171.8 (CO, C-6); HRMS calcd for [C₁₈H₂₁NO₆S + H⁺]: 380.1162, found: 380.1164.

cis-6-Hydroxy-5-(methoxycarbonyl)-8-methyl-1-oxo-1,2,3,4,4a,7,8,8a-octahydroisoquinoline (H-8/H-8a *trans*, **16**). Operating as described in the above general procedure, from a solution of the *N*-Boc derivative **13a** (10 mg, 0.03 mmol) in anhydrous CH₂Cl₂ (600 μ L) and TFA (200 μ L), compound **16** was obtained (7 mg, 99% yield): IR (ATR Pike) ν (cm⁻¹): 3340 (NH), 1659 (CO); ¹H-NMR (400 MHz, CDCl₃, COSY, g-HSQC): δ = 1.12 (d, J = 6.8 Hz, 3H, CH₃), 1.83 (m, 1H, H-4), 1.98 (dd, J = 13.6, 3.6 Hz, 1H, H-4), 2.06 (dd, J = 18.4, 8.8 Hz, H-7), 2.23 (m, 2H, H-8, H-8a), 2.42 (dd, J = 18.4, 4.8 Hz, 1H, H-7), 2.93 (m, 1H, H-4a), 3.23–3.40 (m, 2H, H-3), 3.79 (s, 3H, CH₃O), 6.22 (br.s, 1H, NH), 12.29 (s, 1H, OH); ¹³C-NMR (100.6 MHz, CDCl₃): δ = 19.1 (CH₃), 25.7 (C-4), 27.3 (C-8, C-8a), 31.0 (C-4a), 37.1 (C-7), 41.1 (C-3), 51.6 (CH₃O), 99.1 (C-5), 172.2, 172.4 (CO, C-6); HRMS calcd for [C₁₂H₁₇NO₄ + H⁺]: 240.1230, found: 240.1232.

Supplementary Materials: The following are available online. Copies of ¹H, ¹³C, and NOE NMR spectra, and crystallographic data for **10a** (CCDC 1890851), **12a** (CCDC 1890850), and **12b** (CCDC 1890852). CCDC 1890850–1890852 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk).

Author Contributions: M.A. designed and planned the research; M.P. supervised the experimental work; F.A. and C.A. performed the experimental work and characterized the compounds; E.M. carried out the X-ray analysis; J.B. discussed the results and prepared the manuscript for publication.

Funding: This research was funded by the MINECO/FEDER, Spain (Project CTQ2015-65384-R).

Acknowledgments: Financial support from the MINECO/FEDER, Spain (Project CTQ2015-65384-R) is gratefully acknowledged. Thanks are also due to the MINECO (Spain) for a fellowship to F. A. (AP2010-1663). We also acknowledge the networking contribution from the COST Action CM1407.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Taylor, D.R.; MacCoss, M.; Lawson, A.D.G. Rings in drugs. *J. Med. Chem.* **2014**, *57*, 5845–5859. [[CrossRef](#)] [[PubMed](#)]
2. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274. [[CrossRef](#)] [[PubMed](#)]
3. Brown, R.T. The yohimbine group. Monoterpenoid Indole Alkaloids. In *The Chemistry of Heterocyclic Compounds*; Saxton, J.E., Ed.; John Wiley and Sons: New York, NY, USA, 1983; Volume 25, pp. 147–200.
4. Szántay, C.; Honty, K. The yohimbine group. Monoterpenoid Indole Alkaloids. In *The Chemistry of Heterocyclic Compounds*; Saxton, J.E., Ed.; John Wiley and Sons: New York, NY, USA, 1994; Volume 25, pp. 161–216.
5. Peng, J.; Rao, K.V.; Choo, Y.-M.; Hamann, M.T. Manzamine alkaloids. In *Modern Alkaloids: Structure, Isolation, Synthesis and Biology*; Fattorusso, E., Tagliatela-Scafati, O., Eds.; Wiley-VCH: Weinheim, Germany, 2008; pp. 189–232.
6. Amat, M.; Perez, M.; Ballette, R.; Proto, S.; Bosch, J. The alkaloids of the madangamine group. In *The Alkaloids*; Knölker, H.-J., Ed.; Elsevier: Oxford, UK, 2015; Volume 74, pp. 159–199.
7. Kaldor, S.W.; Kalish, V.J.; Davies, J.F., II; Shetty, B.V.; Fritz, J.E.; Appelt, K.; Burgess, J.A.; Campanale, K.M.; Chirgadze, N.Y.; Clawson, D.K.; et al. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. *J. Med. Chem.* **1997**, *40*, 3979–3985. [[CrossRef](#)] [[PubMed](#)]

8. Arusksakunwong, O.; Promsri, S.; Witta, K.; Nimmanpipug, P.; Lee, V.S.; Wijitkosoom, A.; Sompornpisut, P.; Hannongbua, S. Current development on HIV-1 protease inhibitors. *Curr. Comput. Aided Drug Des.* **2007**, *3*, 201–213. [[CrossRef](#)]
9. Weiss, B.; Alt, A.; Ogden, A.M.; Gates, M.; Dieckman, D.K.; Clemens-Smith, A.; Ho, K.H.; Jarvie, K.; Rizkalla, G.; Wright, R.A.; et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. *Pharmacol. Exp. Ther.* **2006**, *318*, 772–781. [[CrossRef](#)] [[PubMed](#)]
10. Motani, A.S.; Luo, J.; Liang, L.; Mihalic, J.T.; Chen, X.; Tang, L.; Li, L.; Jaen, J.; Chen, J.-L.; Dai, K. Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models. *Pharmacol. Res. Perspect.* **2013**, *1*, e00003. [[CrossRef](#)] [[PubMed](#)]
11. Martin, S.F.; Williamson, S.A.; Gist, R.P.; Smith, K.M. Aspects of the intramolecular Diels-Alder reactions of some 1,3,9-trienic amides, amines, and esters. An approach to the pentacyclic skeleton of the yohimboid alkaloids. *J. Org. Chem.* **1983**, *48*, 5170–5180. [[CrossRef](#)]
12. Moriwake, T.; Hamano, S.; Saito, S.; Torii, S.; Kashino, S. Synthesis of the chiral (8S)-7-aza-1,3(E),9-decatriene system from natural. α -Amino acids and its intramolecular Diels-Alder reaction directed toward chiral trans-hydroisoquinolones. *J. Org. Chem.* **1989**, *54*, 4114–4120. [[CrossRef](#)]
13. Casamitjana, N.; López, V.; Jorge, A.; Bosch, J.; Molins, E.; Roig, A. Diels-Alder reactions of 5,6-dihydro-2(1H)-pyridones. *Tetrahedron* **2000**, *56*, 4027–4042. [[CrossRef](#)]
14. Zibuck, R. *t*-Butyl (*E*)-3-oxo-4-hexenoate. In *Encyclopedia of Reagents for Organic Synthesis*; Paquette, L.A., Ed.; Wiley: Chichester, UK, 1995; Volume 2, pp. 936–937.
15. Zibuck, R. Methyl 3-oxo-4-pentenoate. In *Encyclopedia of Reagents for Organic Synthesis*; Paquette, L.A., Ed.; Wiley: Chichester, UK, 1995; Volume 5, pp. 3558–3559.
16. Audran, G.; Brémond, P.; Feuerstein, M.; Marque, S.R.A.; Santelli, M. Nazarov reagents and their use in organic synthesis. *Tetrahedron* **2013**, *69*, 8325–8348. [[CrossRef](#)]
17. Amat, M.; Arioli, F.; Pérez, M.; Molins, E.; Bosch, J. Preparation and double Michael addition reactions of a synthetic equivalent of the Nazarov reagent. *Org. Lett.* **2013**, *15*, 2470–2473. [[CrossRef](#)] [[PubMed](#)]
18. Arioli, F.; Pérez, M.; Are, C.; Estarellas, C.; Luque, F.J.; Bosch, J.; Amat, M. Stereocontrolled annulations of indolo[2,3-*a*]quinolizidine-derived lactams with a silylated Nazarov reagent. Access to allo and epiallo yohimbine-type derivatives. *Chem. Eur. J.* **2015**, *21*, 13382–13389. [[CrossRef](#)] [[PubMed](#)]
19. Estarellas, C.; Arioli, F.; Pérez, M.; Are, C.; Hevia, D.; Molins, E.; Luque, F.J.; Bosch, J.; Amat, M. Origin of the base-dependent facial selectivity in annulation reactions of Nazarov-type reagents with unsaturated indolo[2,3-*a*]quinolizidine lactams. *Eur. J. Org. Chem.* **2017**, 3969–3979. [[CrossRef](#)]
20. Lavallée, J.-F.; Deslongchamps, P. Synthesis of *cis*-decalin via Diels-Alder and double Michael cycloaddition with substituted Nazarov reagent. *Tetrahedron Lett.* **1988**, *29*, 5117–5118. [[CrossRef](#)]
21. Lavallée, J.-F.; Spino, C.; Ruel, R.; Hogan, K.T.; Deslongchamps, P. Stereoselective synthesis of *cis*-decalins via Diels-Alder and double Michael addition of substituted Nazarov reagents. *Can. J. Chem.* **1992**, *70*, 1406–1426. [[CrossRef](#)]
22. Jung, Y.C.; Yoon, C.H.; Turos, E.; Yoo, K.S.; Jung, K.J. Total Syntheses of (–)- α -kainic acid and (+)- α -allokainic acid via stereoselective C-H insertion and efficient 3,4-stereocontrol. *J. Org. Chem.* **2007**, *72*, 10114–10122. [[CrossRef](#)] [[PubMed](#)]

Sample Availability: Samples of the compounds are not available from the authors.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).